| pubmed-article:21334892 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21334892 | lifeskim:mentions | umls-concept:C0006864 | lld:lifeskim |
| pubmed-article:21334892 | lifeskim:mentions | umls-concept:C1413554 | lld:lifeskim |
| pubmed-article:21334892 | lifeskim:mentions | umls-concept:C0243076 | lld:lifeskim |
| pubmed-article:21334892 | lifeskim:mentions | umls-concept:C0201734 | lld:lifeskim |
| pubmed-article:21334892 | lifeskim:mentions | umls-concept:C0679622 | lld:lifeskim |
| pubmed-article:21334892 | lifeskim:mentions | umls-concept:C0205314 | lld:lifeskim |
| pubmed-article:21334892 | pubmed:issue | 7 | lld:pubmed |
| pubmed-article:21334892 | pubmed:dateCreated | 2011-3-14 | lld:pubmed |
| pubmed-article:21334892 | pubmed:abstractText | The pharmacokinetic based optimisation of a novel series of indole-2-carboxamide antagonists of the cannabinoid CB(1) receptor is disclosed. Compound 24 was found to be a highly potent and selective cannabinoid CB(1) antagonist with high predicted human oral bioavailability. | lld:pubmed |
| pubmed-article:21334892 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21334892 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21334892 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21334892 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21334892 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21334892 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21334892 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21334892 | pubmed:issn | 1464-3405 | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:BakerJamesJ | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:ClarkJohn KJK | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:WardNickN | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:MartinIainI | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:CowleyPhillip... | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:WishartGrantG | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:WalkerGlennG | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:CarlyleIanI | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:EdwardsDarren... | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:BuchananKirst... | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:ClarksonThoma... | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:DeehanMaureen... | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:KiyoiYasukoY | lld:pubmed |
| pubmed-article:21334892 | pubmed:author | pubmed-author:OsbournDawnD | lld:pubmed |
| pubmed-article:21334892 | pubmed:copyrightInfo | Copyright © 2011 Elsevier Ltd. All rights reserved. | lld:pubmed |
| pubmed-article:21334892 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21334892 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21334892 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:21334892 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21334892 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21334892 | pubmed:pagination | 2034-9 | lld:pubmed |
| pubmed-article:21334892 | pubmed:meshHeading | pubmed-meshheading:21334892... | lld:pubmed |
| pubmed-article:21334892 | pubmed:meshHeading | pubmed-meshheading:21334892... | lld:pubmed |
| pubmed-article:21334892 | pubmed:meshHeading | pubmed-meshheading:21334892... | lld:pubmed |
| pubmed-article:21334892 | pubmed:meshHeading | pubmed-meshheading:21334892... | lld:pubmed |
| pubmed-article:21334892 | pubmed:meshHeading | pubmed-meshheading:21334892... | lld:pubmed |
| pubmed-article:21334892 | pubmed:meshHeading | pubmed-meshheading:21334892... | lld:pubmed |
| pubmed-article:21334892 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21334892 | pubmed:articleTitle | Pharmacokinetic optimisation of novel indole-2-carboxamide cannabinoid CB1 antagonists. | lld:pubmed |
| pubmed-article:21334892 | pubmed:affiliation | Department of Chemistry, MSD, Newhouse, Lanarkshire ML1 5SH, UK. phillip.cowley@tppgd.com | lld:pubmed |
| pubmed-article:21334892 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | http://linkedlifedata.com/r... | pubmed-article:21334892 | lld:chembl |
